{"organizations": [], "uuid": "622d6f5719609d83c6c356799771ba3dd9a75166", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180125.html", "section_title": "Archive News &amp; Video for Thursday, 25 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-cti-biopharma-provides-corporate-a/brief-cti-biopharma-provides-corporate-and-european-regulatory-update-idUSASB0C2HY", "country": "US", "domain_rank": 408, "title": "BRIEF-CTI Biopharma Provides Corporate And European Regulatory Update", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.49, "site_type": "news", "published": "2018-01-26T05:55:00.000+02:00", "replies_count": 0, "uuid": "622d6f5719609d83c6c356799771ba3dd9a75166"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-cti-biopharma-provides-corporate-a/brief-cti-biopharma-provides-corporate-and-european-regulatory-update-idUSASB0C2HY", "ord_in_thread": 0, "title": "BRIEF-CTI Biopharma Provides Corporate And European Regulatory Update", "locations": [], "entities": {"persons": [], "locations": [{"name": "delaware", "sentiment": "none"}, {"name": "co", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "cti biopharma corp", "sentiment": "negative"}, {"name": "cti biopharma", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "pacritinib", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 25 (Reuters) - CTI Biopharma Corp:\n* CTI BIOPHARMA PROVIDES CORPORATE AND EUROPEAN REGULATORY UPDATE\n* CTI BIOPHARMA - WAS GRANTED 3 MONTH EXTENSION TO SUBMIT ITS RESPONSE TO DAY 120 LIST OF QUESTIONS FOR HUMAN USE OF EMA, REGARD TO MAA FOR PACRITINIB\n* CTI BIOPHARMA CORP - CO ANTICIPATES SUBMITTING ITS RESPONSE TO D120 LOQ IN MAY 2018\n* CTI BIOPHARMA CORP - CO REINCORPORATED IN STATE OF DELAWARE, DELISTED FROM BORSA ITALIANA MTA EXCHANGE Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-26T05:55:00.000+02:00", "crawled": "2018-01-26T21:30:42.000+02:00", "highlightTitle": ""}